NCT03922100

Study of NMS-03592088 in Patients With Relapsed or Refractory AML or CMML

A Phase I/II Study of NMS-03592088, a FLT3, KIT and CSF1R Inhibitor, in Patients With Relapsed or Refractory AML or CMML

• Status: Terminated
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 63 (actual)
• Sponsor: Nerviano Medical Sciences · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to explore safety, tolerability, including the maximum tolerated dose and the recommended Phase II dose (RP2D), and antitumor activity of NMS-03592088 in adult patients with relapsed or refractory Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML).

Conditions

• Acute Myeloid Leukemia (AML)
• Chronic Myelomonocytic Leukemia (CMML)

Interventions

Type	Name	Description
DRUG	NMS-03592088	Route of administration: Oral

Timeline

• Start date: 2019-04-03
• Primary completion: 2024-08-29
• Completion: 2024-08-29
• First posted: 2019-04-19
• Last updated: 2026-03-18
• Results posted: 2026-03-18

Locations

11 sites across 3 countries: France, Italy, Spain

Regulatory

• FDA-regulated drug study